Cargando…

Exploring Pharmacogenetic Testing for Hypertension Management in China

Detalles Bibliográficos
Autores principales:	Zhao, Zhenping, Zhou, Maigeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515647/ https://www.ncbi.nlm.nih.gov/pubmed/37745264 http://dx.doi.org/10.46234/ccdcw2023.149

Ejemplares similares

Encountering Pharmacogenetic Test Results in the Psychiatric Clinic
por: Bousman, Chad A, et al.
Publicado: (2021)

Delivering pharmacogenetic testing in a primary care setting
por: Mills, Rachel, et al.
Publicado: (2013)

Pharmacogenetics in the Management of Coumarin Anticoagulant Therapy: The Way Forward or an Expensive Diversion?
por: Greaves, Mike
Publicado: (2005)

The effect gap of hypertension health management services in poverty and non-poverty counties on the hypertension control: evidence from China Chronic Diseases Risk Factors Surveillance
por: Jiang, Bo, et al.
Publicado: (2023)

Pharmacogenetics of cancer therapy: breakthroughs from beyond?
por: Lu, Da-Yong, et al.
Publicado: (2015)

Pharmacogenetics and pharmacogenomics in glaucoma therapeutics: the way to personalized therapy
por: Liao, Shiyu, et al.
Publicado: (2023)

How informative is a negative finding in a small pharmacogenetic study?
por: Bacanu, S-A, et al.
Publicado: (2012)

Pharmacogenetics in Africa, an Opportunity for Appropriate Drug Dosage Regimens: on the Road to Personalized Healthcare
por: Masimirembwa, C, et al.
Publicado: (2013)

Digital Technologies: Advancing Individualized Treatments through Gene and Cell Therapies, Pharmacogenetics, and Disease Detection and Diagnostics
por: Corridon, Peter R., et al.
Publicado: (2022)

Pharmacogenetic Labeling of FDA-Approved Drugs: A Regulatory Retrospective
por: Drozda, Katarzyna, et al.
Publicado: (2018)

Therapeutic Drug Monitoring and Pharmacogenetic Testing in Northern China
por: Zhang, Chunyan, et al.
Publicado: (2021)

Hypertension Prevalence, Awareness, Treatment, Control, and Associated Factors in the Labor Force Population — China, 2015
por: Guan, Yunqi, et al.
Publicado: (2020)

Recent advances and future directions for the pharmacogenetic basis of anti-VEGF treatment response in neovascular age-related macular degeneration
por: Riaz, Moeen, et al.
Publicado: (2017)

Growing Burden of Hypertension in China: Causes, Challenges, and Opportunities
por: Shi, Zumin, et al.
Publicado: (2020)

Exploring perceptions, knowledge, and attitudes regarding pharmacogenetic testing in the medically underserved
por: Gawronski, Brian E., et al.
Publicado: (2023)

PREEMPTIVE PHARMACOGENETIC TESTING: EXPLORING THE KNOWLEDGE AND PERSPECTIVES OF UNITED STATES PAYERS
por: Keeling, Nicholas J., et al.
Publicado: (2017)

Hypertension management in 2030: a kaleidoscopic view
por: Kulkarni, Spoorthy
Publicado: (2020)

Revising the hemodynamic criteria for pulmonary hypertension: A perspective from China
por: Xiong, Changming, et al.
Publicado: (2023)

Pharmacological management of portal hypertension: current status and future
por: Gao, Zhu-Qing, et al.
Publicado: (2020)

Sex and gender differences in the management of chronic kidney disease and hypertension
por: Mayne, Kaitlin J., et al.
Publicado: (2023)

Feasibility of Precision Medicine in Hypertension Management—Scope and Technological Aspects
por: Nitzan, Meir, et al.
Publicado: (2022)

The landscape of pharmacogenetic testing in a US managed care population
por: Anderson, Heather D., et al.
Publicado: (2020)

The Landscape of Clinical Implementation of Pharmacogenetic Testing in Central China: A Single-Center Study
por: Zhang, Jingmin, et al.
Publicado: (2021)

Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings
por: Smith, D. Max, et al.
Publicado: (2020)

Leisure-Time Physical Activity Among Chinese Adults — China, 2015
por: Li, Chun, et al.
Publicado: (2020)

Updates to the NASA human system risk management process for space exploration
por: Antonsen, Erik L., et al.
Publicado: (2023)

The Role of Rapid Diagnostic Tests in Managing Malaria
por: Bisoffi, Zeno, et al.
Publicado: (2009)

EXPERIENCE OF PHARMACOGENETIC TESTING IN THE TREATMENT OF ANTIPSYCHOTICS
por: Kaydan, M., et al.
Publicado: (2023)

The Potential Utility of Pharmacogenetic Testing in Psychiatry
por: Gardner, Kathryn R., et al.
Publicado: (2014)

Variant Interpretation in Current Pharmacogenetic Testing
por: Luvsantseren, Sally, et al.
Publicado: (2020)

The Utility of Pharmacogenetics Testing in Psychiatric Populations
por: Jürgens, Gesche
Publicado: (2021)

Current concepts and molecular mechanisms in pharmacogenetics of essential hypertension
por: Rahman, Farhana, et al.
Publicado: (2021)

Community-based integration of management of non-communicable diseases in China
por: Xiao, Yue
Publicado: (2015)

More accurate systolic blood pressure measurement is required for improved hypertension management: a perspective
por: Nitzan, Meir, et al.
Publicado: (2017)

Management of Medical Technology under the New Medical Policy Background in China
por: Wu, Suo-Wei, et al.
Publicado: (2016)

COVID-19 waste management: Effective and successful measures in Wuhan, China
por: Singh, Narendra, et al.
Publicado: (2020)

Breast Cancer Screening Coverage — China, 2018–2019
por: Zhang, Mei, et al.
Publicado: (2023)

Pharmacogenetic testing in the Veterans Health Administration: Policy recommendations from the VHA Clinical Pharmacogenetics Subcommittee
por: Vassy, Jason L., et al.
Publicado: (2018)

Pharmacogenetic testing among patients with depression in a US managed care population
por: Anderson, Heather D., et al.
Publicado: (2022)

Development and Validation of a Self-Administered Screening Test for Betel Quid Use Disorders in Betel Quid Chewers in Hunan, China
por: Yang, Lei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hg0k7f5f40ikpkfq0f6koit6mc